
Liraglutide
Products


Information
Diabetes mellitus, Liraglutide is a once-daily GLP-1 derivative for the treatment of type 2 diabetesLabel,2. The prolonged action of liraglutide is achieved by attaching a fatty acid molecule at position 26 of the GLP-1 molecule, enabling it to bind reversibly to albumin within the subcutaneous tissue and bloodstream and be released slowly over timeLabel,2,3. Binding with albumin results in slower degradation and reduced elimination of liraglutide from the circulation by the kidneys compared to GLP-12,3. The effect of liraglutide is the increased secretion of insulin and decreased secretion of glucagon in response to glucose as well as slower gastric emptyingLabel. Liraglutide also does not adversely affect glucagon secretion in response to low blood sugar
Distribution Areas
North America (USA, Canada)Middle East Region (e.g. UAE)Central America (e.g. Mexico)Europe - EU countriesEurope - non EU (e.g. UK, Russia, ex-CIS countries)South America (e.g. Brazil, Colombia)
Supplied From
China
All categories
PeptidesBiopharmaceutical ProductsAPIs (Active Pharmaceutical Ingredients)Innovative APIsProducts
Main Categories
Biopharmaceutical ProductsAPIs (Active Pharmaceutical Ingredients)
